IMPAX LABORATORIES INC
10QSB, EX-27, 2000-07-31
PHARMACEUTICAL PREPARATIONS
Previous: IMPAX LABORATORIES INC, 10QSB, 2000-07-31
Next: ASHTON TECHNOLOGY GROUP INC, DEF 14A, 2000-07-31



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET (UNAUDITED) AND THE CONSOLIDATED STATEMENT OF INCOME
FOR THE SIX MONTHS ENDED JUNE, 2000(UNAUDITED) AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>      1,000

<S>                                 <C>
<PERIOD-TYPE>              6-MOS
<FISCAL-YEAR-END>                                  DEC-31-2000
<PERIOD-START>                                     JAN-01-2000
<PERIOD-END>                                       JUN-30-2000
<CASH>                                                   6,879
<SECURITIES>                                             5,815
<RECEIVABLES>                                            3,317
<ALLOWANCES>                                                75
<INVENTORY>                                              5,612
<CURRENT-ASSETS>                                        22,492
<PP&E>                                                  12,168
<DEPRECIATION>                                           2,467
<TOTAL-ASSETS>                                          69,634
<CURRENT-LIABILITIES>                                    9,562
<BONDS>                                                      0
<COMMON>                                                   249
                                   37,000
                                                  0
<OTHER-SE>                                              20,898
<TOTAL-LIABILITY-AND-EQUITY>                            69,634
<SALES>                                                  5,426
<TOTAL-REVENUES>                                         5,426
<CGS>                                                    4,559
<TOTAL-COSTS>                                            4,559
<OTHER-EXPENSES>                                        10,779
<LOSS-PROVISION>                                             0
<INTEREST-EXPENSE>                                           0
<INCOME-PRETAX>                                         (9,539)
<INCOME-TAX>                                                 0
<INCOME-CONTINUING>                                          0
<DISCONTINUED>                                               0
<EXTRAORDINARY>                                              0
<CHANGES>                                                    0
<NET-INCOME>                                            (9,539)
<EPS-BASIC>                                               (.38)
<EPS-DILUTED>                                             (.38)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission